Selecting Between DRd and VRd Combination Regimens for Patients With Transplant-Ineligible NDMM
A panel of experts explain how they select between the DRd (daratumumab, lenalidomide, dexamethasone) and VRd (bortezomib, lenalidomide, dexamethasone) treatment regimens for patients with transplant-ineligible newly diagnosed multiple myeloma.
EP: 1.Clinical Scenario: A 61-Year-Old Woman with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM)
EP: 2.Induction Treatment Regimens for Patients With Transplant-Eligible NDMM
EP: 3.Treatment Strategies for Patients With High-Risk NDMM
EP: 4.Clinical Scenario: A 68-Year-Old Man With Transplant-Ineligible NDMM
Now Viewing
EP: 5.Selecting Between DRd and VRd Combination Regimens for Patients With Transplant-Ineligible NDMM
EP: 6.Factors for Consideration When Treating Frail Patients With Transplant-Ineligible NDMM
EP: 7.Bone Disease Prophylaxis in Patients With Transplant-Eligible NDMM
EP: 8.Clinical Scenario: A 61-Year-Old Woman With Relapsed/Refractory Multiple Myeloma (R/R MM)
EP: 9.Choosing Between Bispecific or CAR T-Cell Therapy for Patients With Multiple Myeloma
EP: 10.Toxicity Management in Patients With Multiple Myeloma
EP: 11.Expert Perspectives on Quadruplet Therapy Regimens for Patients With Multiple Myeloma
EP: 12.Looking Ahead in the Multiple Myeloma Treatment Landscape
EP: 13.CAR T-Cell Therapy Vs Bispecific Antibodies As Multiple Myeloma Treatment
Recent Videos
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
Related Content
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025Podcast
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
